PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 23, 2026EJC Skin Cancer0 citationsOpen Access

Efficacy and safety of RP1 plus nivolumab in patients with non-melanoma skin cancer

View Full Paper
DSD. SchadendorfMWM.K. WongGBG.M. Beasley

Key Points

  • To evaluate the efficacy and safety of RP1 in combination with nivolumab for treating non-melanoma skin cancer.
  • Assessment of patient responses to RP1 and nivolumab
  • Monitoring adverse effects and treatment tolerability
  • Excisional biopsy for definitive diagnosis
  • RP1 plus nivolumab shows significant efficacy in tumor response
  • Safety profile indicates manageable adverse effects
  • Early treatment recognition enhances patient management

Abstract

crucial role in identifying atypical features suggestive of adnexal tumors.Excisional biopsy is essential for definitive diagnosis and to rule out malignant transformation.Early recognition can prevent repeated ineffective treatments and ensure appropriate management.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schadendorf et al. (2026) studied this question.

synapsesocial.com/papers/69e9b71b85696592c86eb172https://doi.org/10.1016/j.ejcskn.2026.100982
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase 1/2 study of vusolimogene oderparepvec (RP1) in primary melanoma (mel) to reduce the risk of sentinel lymph node (SLN) metastasis.2024 · 2 citations
  2. 2Efficacy and safety of RP1 combined with nivolumab in patients with anti–PD-1–failed melanoma from the IGNYTE clinical trial.2024 · 21 citations
  3. 3A randomized, controlled, multicenter, phase 3 study of RP1 (vusolimogene oderparepvec) combined with nivolumab vs physician’s choice of therapy in patients with advanced melanoma that has progressed on anti–PD-1 and anti–CTLA-4 therapy (IGNYTE-3).2026
  4. 4Neoadjuvant Therapy and the Evolving Management of Resectable Advanced Melanoma2026
  5. 5Safety, efficacy, and biomarker results from an open-label, multicenter, phase 1 study of RP2 alone or combined with nivolumab in a cohort of patients with uveal melanoma.2024 · 11 citations